Current nucleos(t)ide analogue therapy for chronic hepatitis B

Gut and Liver

Volumn 5, Issue 3, 2011, Pages 278-287

  Kim, Soon Sun ^a   Cheong, Jae Youn ^a   Cho, Sung Won ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Drug resistance; Hepatitis B virus; Nucleos(t)ide analogue

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CLEVUDINE; CREATININE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CANCER PREVENTION; CREATININE CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; GENE MUTATION; GENETIC RESISTANCE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONHUMAN; PATIENT COMPLIANCE; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; REVIEW; VIRUS LOAD;

EID: 80052500137     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2011.5.3.278     Document Type: Review

References (80)

1. Kim S.B., Lee W.K., Choi H., et al. A study on viral hepatitis markers and abnormal liver function test in adults living in northwest area of Chungnam. Korean J Gastroenterol 2009;53:355-360.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
3. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
4. DiBisceglie A., Lai C.L., Gane E., et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside treated hepatitis B patients. Hepatology 2006;44(Suppl 1):230A.
5. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
6. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686. (Pubitemid 43374518)
7. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004;64:1-15. (Pubitemid 39307089)
8. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661. (Pubitemid 26001954)
9. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263. (Pubitemid 29489740)
10. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68. (Pubitemid 28304879)
11. Schalm S.W., Heathcote J., Cianciara J., et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000;46:562-568. (Pubitemid 30305823)
12. Chang T.T., Lai C.L., Chien R.N., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-1282.
13. Yao G.B., Zhu M., Cui Z.Y., Wang B.E., Yao J.L., Zeng M.D. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009;10:131-137.
14. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32(4 Pt 1):847-851.
15. Lok A.S., Hussain M., Cursano C., et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153.
16. Fung S.K., Wong F., Hussain M., Lok A.S. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004;11:432-438. (Pubitemid 39336224)
17. Lee H.J., Eun R., Jang B.I., Kim T.N. Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus. Gut Liver 2007;1:151-158.
18. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
19. Nikolaidis N., Vassiliadis T., Giouleme O., et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005;19:321-326. (Pubitemid 40711964)
20. Dienstag J.L., Cianciara J., Karayalcin S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-755. (Pubitemid 36397384)
21. Lee K.M., Cho S.W., Kim S.W., Kim H.J., Hahm K.B., Kim J.H. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-212. (Pubitemid 36005519)
22. Song B.C., Suh D.J., Lee H.C., Chung Y.H., Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32(4 Pt 1):803-806.
23. Cha C.K., Kwon H.C., Cheong J.Y., et al. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol 2009;81:417-424.
24. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722. (Pubitemid 37500436)
25. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34(4 Pt 1):785-791. (Pubitemid 32928004)
26. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816. (Pubitemid 36245757)
27. Marcellin P., Chang T.T., Lim S.G., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-758.
28. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681. (Pubitemid 41007822)
29. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807. (Pubitemid 36245756)
30. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751. (Pubitemid 44958517)
31. Lim S.G., Marcellin P., Tassopoulos N., et al. Clinical trial: Effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2007;26:1419-1428. (Pubitemid 350045604)
32. Angus P., Vaughan R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297. (Pubitemid 36929407)
33. Villeneuve J.P., Durantel D., Durantel S., et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-1089. (Pubitemid 37523785)
34. Westland C.E., Yang H., Delaney W.E. 4th, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103. (Pubitemid 36775800)
35. Fung S.K., Chae H.B., Fontana R.J., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-290. (Pubitemid 43069209)
36. Lee Y.S., Suh D.J., Lim Y.S., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-1391. (Pubitemid 43980117)
37. Lee J.M., Park JY, Kim do Y, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235-241.
38. Chang T.T., Gish R.G., De Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. (Pubitemid 43357804)
39. Leung N., Peng C.Y., Hann H.W., et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-79.
40. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020. (Pubitemid 43357805)
41. Shim J.H., Lee H.C., Kim K.M., et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-182.
42. Gish R.G., Lok A.S., Chang T.T., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1444. (Pubitemid 350029745)
43. Shouval D., Lai C.L., Chang T.T., et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-295.
44. Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
45. Fournier C., Zoulim F. Antiviral therapy of chronic hepatitis B: Prevention of drug resistance. Clin Liver Dis 2007;11:869-892, ix. (Pubitemid 350027768)
46. Lai C.L., Gane E., Liaw Y.F., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588. (Pubitemid 350294224)
47. Liaw Y.F., Gane E., Leung N., et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
48. Zeuzem S., Gane E., Liaw Y.F., et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20.
49. Moon Y.M., Hwang S.G., Kim B.S., et al. The efficacy and safety of telbivudine in Korean patients with chronic hepatitis B. Korean J Hepatol 2007;13:503-512.
50. Lok A.S., Zoulim F., Locarnini S., et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-265. (Pubitemid 47171942)
51. Marcellin P., Heathcote E.J., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
52. Heathcote E.J., Marcellin P., Buti M., et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
53. Liaw Y.F., Sheen I.S., Lee C.M., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62- 72.
54. Van Bömmel F., De Man R.A., Wedemeyer H., et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.
55. Sheldon J., Camino N., Rodés B., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-734. (Pubitemid 41376852)
56. Amini-Bavil-Olyaee S., Herbers U., Sheldon J., Luedde T., Trautwein C., Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1158-1165.
57. Balakrishna Pai S., Liu S.H., Zhu Y.L., Chu C.K., Cheng Y.C. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L- arabinofuranosyl uracil. Antimicrob Agents Chemother 1996;40:380-386.
58. Chu C.K., Boudinot F.D., Peek S.F., et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998;3(Suppl 3):113-121. (Pubitemid 28528327)
59. Ma T., Pai S.B., Zhu Y.L., et al. Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem 1996;39:2835-2843. (Pubitemid 26240351)
60. Yoo B.C., Kim J.H., Chung Y.H., et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-1178.
61. Lau G.K., Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol 2010;16:315-320.
62. Kim I.H., Lee S., Kim S.H., et al. Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B. J Korean Med Sci 2010;25:738-745.
63. Yoo B.C., Kim J.H., Kim T.H., et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-1048.
64. Tak W.Y., Park S.Y., Cho C.M., et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53:261-266.
65. Kim H.J., Park D.I., Park J.H., et al. Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B. Liver Int 2010;30:834-840.
66. Kwon S.Y., Park Y.K., Ahn S.H., et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol 2010;84:4494-4503.
67. Lee H.J., Eun J.R., Lee C.H., et al. Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases. Korean J Hepatol 2009;15:179-192.
68. Chang T.T., Lai C.L., Kew Yoon S., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430.
69. Suzuki F., Akuta N., Suzuki Y., et al. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol 2010;25:892-898.
70. Yuen M.F., Fung J., Seto W.K., Wong D.K., Yuen J.C., Lai C.L. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antivir Ther 2009;14:679-685.
71. Rapti I., Dimou E., Mitsoula P., Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-313. (Pubitemid 46374587)
72. Lampertico P., Viganò M., Manenti E., Iavarone M., Lunghi G., Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-1419. (Pubitemid 43260045)
73. Lampertico P., Viganò M., Manenti E., Iavarone M., Sablon E., Colombo M. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-1451. (Pubitemid 350047463)
74. Cho S.W., Cho Y.J., Cheong J.Y., et al. Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients. Korean J Gastroenterol 2010;56:83-89.
75. Van Bömmel F., Trojan J., Feucht H.H., et al. Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir. Hepatology 2007;46(Suppl 1):664A.
76. Patterson S.J., George J., Strasser S.I., et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247-254.
77. Cho S.W., Koh K.H., Cheong J.Y., et al. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 2010;17:171-177.
78. Shim J.H., Suh D.J., Kim K.M., et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009;50:1064-1071.
79. Heo N.Y., Lim Y.S., Lee H.C., Chung Y.H., Lee Y.S., Suh D.J. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010;53:449-454.
80. Yang H.J., Lee J.H., Kim Y.J., Yoon J.H., Lee H.S. Lamivudine and adefovir dipivoxil versus entecavir 1.0 mg alone for the treatment of adefovir-resistant mutation which deveolpoed during sequential adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Korean J Hepatol 2009;15(Suppl 3):S50.